PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
Launched by UNIVERSITY HOSPITAL, GHENT · Dec 8, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The PPOS and Corifollitropin Alfa (CFA) Cross-over Study is a clinical trial designed to compare two different methods of ovarian stimulation used in in vitro fertilization (IVF) treatments. The goal is to see how satisfied patients are with each treatment and how well they stick to the treatment plans. Participants will receive both treatments in a crossover design, allowing researchers to compare their experiences and responses. This study will include women aged 18 to 40 who are starting their first IVF treatment. Key eligibility criteria include having a Body Mass Index (BMI) between 18 and 32 and not having any conditions that would prevent ovarian stimulation.
Participants in this study can expect to complete questionnaires about their experiences before, during, and after treatment. They will be closely monitored for their hormonal levels and ovarian response throughout the trial. It's important to note that women who are pregnant, breastfeeding, or taking certain medications are not eligible to participate. The trial is currently not recruiting participants, but it aims to provide valuable insights into which ovarian stimulation method may be more beneficial for women undergoing fertility treatments.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • first ovarian stimulation cycle
- • aged ≥ 18 and \< 41 years old at the time of first OPU
- • Body Mass Index (BMI) ≥ 18 kg/m² and \< 32 kg/m²
- Exclusion Criteria:
- • contra-indication for ovarian stimulation
- • expected poor ovarian response (Bologna Criteria)
- • PCOS patients
- • refusal to fill out questionnaires before, during and after treatment
- • simultaneous participation in another clinical study
- • untreated and uncontrolled thyroid dysfunction;
- • current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;
- • pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported